| [1] | Havlickova A, Czaika VA, Friedrich M (2008) Epidemiological trends in skin mycoses worldwide. Mycoses 51 S4: 2–15. doi: 10.1111/j.1439-0507.2008.01606.x
|
| [2] | Haneke E, Roseeuw D (1999) The scope of onychomycosis: epidemiology and clinical features. Int J Dermatol 38 Suppl 2: 7–12. doi: 10.1046/j.1365-4362.1999.00015.x
|
| [3] | Ogasawara Y (2003) Prevalence and patient's consciousness of tinea pedis and onychomycosis. Nihon Ishinkin Gakkai Zasshi 44: 253–260. doi: 10.3314/jjmm.44.253
|
| [4] | Ghannoum MA, Hajjeh RA, Scher R, Konnikov N, Gupta AK, et al. (2000) A large-scale North American study of fungal isolates from nails: the frequency of onychomycosis, fungal distribution, and antifungal susceptibility patterns. J Am Acad Dermatol 43: 641–648. doi: 10.1067/mjd.2000.107754
|
| [5] | Scher RK (1994) Onychomycosis is more than a cosmetic problem. Br J Dermatol 130: 15. doi: 10.1111/j.1365-2133.1994.tb06087.x
|
| [6] | Gupta AK, Jain HC, Lynde CW, MacDonald P, Cooper EA, et al. (2000) Prevalence and epidemiology of onychomycosis in patients visiting physicians' offices: a multicenter Canadian survey of 15,000 patients. J Am Acad Dermatol 43: 244–248. doi: 10.1067/mjd.2000.104794
|
| [7] | Faergemann J, Correia O, Nowicki R, Ro BI (2005) Genetic predisposition - understanding underlying mechanisms of onychomycosis. J Eur Acad Dermatol Venerol 19: 17–19. doi: 10.1111/j.1468-3083.2005.01283.x
|
| [8] | Lanternier F, Pathan S, Vincent QB, Liu L, Cypowyj S, et al (2013) Deep dermatophytosis and inherited CARD9 deficiency. N Engl J Med 369: 1704–1714. doi: 10.1056/nejmoa1208487
|
| [9] | Saunte DM, Holgersen JB, Haedersdal M, Strauss G, Bitsch M, et al. (2006) Prevalence of toe nail onychomycosis in diabetic patients. Acta Derm Venerol 86: 425–428. doi: 10.2340/00015555-0113
|
| [10] | Nenoff P, Ginter-Hanselmayer G, Tietz HJ (2012) Fungal nail infections - an update: Part 1 - Prevalence, epidemiology, predisposing conditions, and differential diagnosis. Hautarzt 63: 30–38. doi: 10.1007/s00105-011-2251-5
|
| [11] | Scher RK, Baran R (2003) Onychomycosis in clinical practice: factors contributing to recurrence. Br J Dermatol 149: 5–9. doi: 10.1046/j.1365-2133.149.s65.5.x
|
| [12] | Arrese JE, Pierard-Franchimont C, Pierard GE (1996) Fatal hyalohyphomycosis following Fusarium onychomycosis in an immunocompromised patient. Am J Dermatopathol 18: 196–198. doi: 10.1097/00000372-199604000-00014
|
| [13] | Aly R (1994) Ecology and epidemiology of dermatophyte infections. J Am Acad Dermatol 31: S21. doi: 10.1016/s0190-9622(08)81262-5
|
| [14] | Ghannoum MA, Mukherjee PK, Warshaw EM, Evans S, Korman NJ, et al. (2013) Molecular analysis of dermatophytes suggest spread of infection among household members. Cutis 91: 237–246.
|
| [15] | Elewski B, Tavakkol A (2005) Safety and tolerability of oral antifungal agents in the treatment of fungal nail disease: a proven reality. Ther Clin Risk Manag 1: 299–306.
|
| [16] | Tosti A, Piraccini BM, Lorenzi S (2000) Onychomycosis caused by nondermatophyte molds: clinical features and response to treatment of 59 cases. J Am Acad Dermatol 42: 217–224. doi: 10.1016/s0190-9622(00)90129-4
|
| [17] | BlueCross BlueShield of Northeastern New York (2006 November 28) Drug Therapy Guidelines: Antifungal Agents Lamisil (terbinafine), Sporanox (itraconazole), Penlac (ciclopirox), Vfend (voriconazole). Drug P&T Newsletter.
|
| [18] | Lauharanta J (1992) Comparative efficacy and safety of amorolfine nail lacquer 2% versus 5% once weekly. Clin Exp Dermatol 17: 41–43. doi: 10.1111/j.1365-2230.1992.tb00277.x
|
| [19] | Ghannoum MA, Long L, Pfister WR (2009) Determination of the efficacy of terbinafine hydrochloride nail solution in the topical treatment of dermatophytosis in a guinea pig model. Mycoses 52: 35–43. doi: 10.1111/j.1439-0507.2008.01540.x
|
| [20] | Faergemann J, Zehender H, Millerioux L (1994) Levels of terbinafine in plasma, stratum corneum, dermis-epidermis (without stratum corneum), sebum, hair and nails and after 250 mg terbinafine orally once daily for 7 and 14 days. Clin Exp Dermatol 19: 121–126. doi: 10.1111/j.1365-2230.1994.tb01138.x
|
| [21] | Osborne CS, Leitner I, Favre B, Ryder NS (2004) Antifungal drug response in an in vitro model of dermatophyte nail infection. Med Mycol 42: 159–163. doi: 10.1080/13693780310001656803
|
| [22] | Ghannoum M, Isham N, Herbert J, Henry W, Yurdakul S (2011) Activity of TDT 067 (Terbinafine in Transfersome) against Agents of Onychomycosis, as Determined by Minimum Inhibitory and Fungicidal Concentrations. J Clin Microbiol 49: 1716–1720. doi: 10.1128/jcm.00083-11
|
| [23] | Alley MR, Baker SJ, Beutner KR, Plattner J (2007) Recent progress on the topical therapy of onychomycosis. Expert Opin Investig Drugs 16: 157–167. doi: 10.1517/13543784.16.2.157
|
| [24] | Ghannoum M, Isham N, Catalano V (2013) A Second Look at Efficacy Criteria for Onychomycosis: Clinical and Mycological Cure. Br J Dermatol. E-pub ahead of print. doi:10.1111/bjd.12594.
|
| [25] | Gupta AK, Simpson FC (2013) Laser therapy for onychomycosis. J Cutan Med Surg 17: 301–307.
|
| [26] | Harris F, Pierpoint L (2012) Photodynamic therapy based on 5-aminolevulinic acid and its use as an antimicrobial agent. Med Res Rev 32: 1292–1327. doi: 10.1002/med.20251
|
| [27] | Delgado-Charro MB (2012) Iontophoretic drug delivery across the nail. Expert Opin Drug Deliv 9: 91–103. doi: 10.1517/17425247.2012.642364
|
| [28] | Silva JL, Doimo G, Faria DP (2011) The use of high frequency waves to treat onychomycosis: preliminary communication of three cases. An Bras Dermatol 86: 598–600.
|
| [29] | Abadi D, Zderic V (2011) Ultrasound-mediated nail drug delivery system. J Ultrasound Med 30: 1723–1730.
|
| [30] | Yazdanparast SA, Barton RC (2006) Arthroconidia production in Trichophyton rubrum and a new ex vivo model of onychomycosis. J Med Microbiol 55: 1577–1581. doi: 10.1099/jmm.0.46474-0
|
| [31] | Bradley M, Leidich S, Isham N, Elewski B, Ghannoum M (1999) Antifungal susceptibilities and genetic relatedness of serial Trichophyton rubrum isolates from patients with onychomycosis of the toenail. Mycoses 42: 105–110.
|
| [32] | Ghannoum MA, Isham N, Long L (2012) Optimization of an infected shoe model for the evaluation of an ultraviolet shoe sanitizer device. J Am Podiatr Med Assoc 102: 309–313. doi: 10.7547/1020309
|
